Ask Jacki About Health, Stem Cells & Changing Lives


Stem Cell Scientists Make Case For More Research To Defeat Diseases

Over the last few years more scientists are learning what Christian Drapeau and STEMTech have known for years….that adult stem cells make up our bodies renewal system and we can naturally increase their numbers by taking Stem Enhance. Increase your circulating stem cells for optimal health.

Leading stem cell scientists make an impassioned case for renewing humanity and defeating disease.

Blood Stem-Cell Transplant Regimen Reverses Sickle Cell Disease in Adults

Blood Stem-Cell Transplant Regimen Reverses Sickle Cell Disease in Adults

 A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine. The trial was conducted at the NIH Clinical Center in Bethesda, Md., by NIH researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases.

“This trial represents a major milestone in developing a therapy aimed at curing sickle cell disease,” said NIDDK Director Griffin P. Rodgers M.D., a co-author of the paper. “Our modified transplant regimen changes the equation for treating adult patients with severe disease in a safer, more effective way.”

Sickle cell disease is caused by an altered gene that produces abnormal hemoglobin, the protein in normal red blood cells that carries oxygen throughout the body. When affected red cells lose oxygen, they collapse into a sickle, or C, shape and become stiff and sticky. Clumps of these cells block blood flow and can cause severe pain, organ damage from lack of oxygen, and stroke. Anemia often develops in people with the disease because sickle cells die off quickly and bone marrow does not make new ones fast enough.

In trials by other investigators, nearly 200 children with severe sickle cell disease were cured with bone marrow transplants after undergoing a regimen in which their own marrow was completely destroyed with chemotherapy. That regimen, however, had proven too toxic for adults, who have years of accumulated organ damage from the disease and are less able to tolerate complete marrow transplantation.

In contrast to the established method in children, this adult trial sought to reduce toxicity by only partially replacing the bone marrow. The much longer lifespan of normal red blood cells, compared to sickle red blood cells, allows the healthy cells to outlast and completely replace the disease-causing cells.

To achieve this goal, the investigators used a low dose of radiation to the whole body and two drugs, alemtuzumab and sirolimus, to suppress the immune system. Alemtuzumab depletes immune cells, but does not adversely affect blood stem cells. Sirolimus does not block the activation of immune cells, but inhibits their proliferation, creating a balance that potentially helps prevent rejection of the new stem cells.

The radiation favorably conditions the bone marrow, where donor stem cells move in and begin producing new, healthy red blood cells. After a median two and one half years follow-up, all 10 recipients were alive and sickle cell disease was eliminated in nine.

“Our patients have had a remarkable change in their lives,” said John F. Tisdale, M.D., the trial’s principal investigator in the NIH Molecular and Clinical Hematology Branch. “They are no longer being admitted to the hospital for frequent pain crises, they have been able to stop chronic pain medications, go back to school and work, get married and have children. Given these results, our regimen will likely have broad application to other nonmalignant diseases and can be performed at most transplant centers.”

 Transplanted cells or tissue are known as grafts. To reduce the possibility of the immune system’s rejection of the graft or development of graft-versus-host disease, in which immune cells from the donor attack the recipient’s tissues, investigators tested the patient and the potential donor to determine if they are a good immunological match. This is called human leukocyte antigen (HLA) typing.

The investigators performed HLA typing on 112 people with severe sickle cell disease and 169 healthy siblings. Of these, 10 patient-sibling identical matches were found. Blood stem cells collected from the blood of healthy donors were then infused into their siblings, ages 16 to 45 years.

This relatively low toxicity regimen allowed patients to become tolerant to the donor immune cells and to achieve stable mixed donor chimerism. Chimerism is a condition in which an individual has two genetically distinct types of cells in the blood. This mixture of host and donor cells was sufficient to reverse sickle cell disease. In most patients the donor’s red blood cells completely replaced the recipient’s.

“Remarkably, the treatment did not result in graft-versus-host disease for any of the participants,” noted Susan B. Shurin, M.D., acting director of the NHLBI. GVHD is a common complication of stem cell transplantation and can lead to serious problems, such as rash, diarrhea and nausea, liver disease, or death. “We are continuing to explore better treatments with fewer side effects to help the millions of sickle cell patients worldwide. This is a very important study because it lessens the toxicity of a therapy known to be highly effective.”

 In the United States, approximately 80,000 people have sickle cell disease, found mainly in people of African ancestry. It occurs to a lesser extent in people of Hispanic, Middle Eastern, Asian and white ancestry. Worldwide, millions of people have sickle cell disease. The pain and complications associated with sickle cell disease can have a profound impact on patients’ quality of life, ability to work, and long-term health and well-being.

One of the main obstacles in treating a larger number of African-Americans with sickle cell disease is the relative lack of an available HLA-matched donor. Dr. Tisdale explained, “Most white Americans can easily find a matched donor in the unrelated bone marrow or cord blood registries; yet when we screened a number of the people in our trial who were without an HLA-matched sibling donor, we could not find a compatible unrelated donor.”

However, there may be a way beyond this health care disparity, Tisdale indicated. If participants in the current trial continue to do well with their transplants it may be possible to move to what he calls “haplo-transplantation,” or a half-match from a sibling, parent or child. “This would allow most people with sickle cell disease to be treated and enjoy a better quality of life,” he said.

 The NIH Clinical Center’s Department of Laboratory Medicine and Transfusion Medicine provided clinical laboratory and transfusion medicine support and patient care for the stem cell donors and transplantation recipients in trial. The Sidney Kimmel Cancer Center at Johns Hopkins Medical Institute provided conceptual input into the design of the trial’s immunological component. The trial is registered as NCT00061568 in www.clinicaltrials.gov.

Health care providers — and sickle cell patients and family members who may be interested in joining NIH blood stem-cell transplant studies — may call 301-402-6466 for more information. Calls will be returned within 48 hours. To search for other clinical trials, visit www.clinicaltrials.gov.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

 The NIH Clinical Center (CC) is the clinical research hospital for the National Institutes of Health. Through clinical research, physician-investigators translate laboratory discoveries into better treatments, therapies and interventions to improve the nation’s health. For more information, visit http://clinicalcenter.nih.gov.

Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at: www.nhlbi.nih.gov.

 NIDDK, part of NIH, conducts and supports basic and clinical research and research training on some of the most common, severe and disabling conditions affecting Americans. The Institute’s research interests include: diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic and hematologic diseases. For more information, visit www.niddk.nih.gov.

The National Institutes of Health (NIH) — The Nation’s Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

 ——————————————————————————–

More information on sickle cell disease is available at: www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_WhatIs.html  and http://diabetes.niddk.nih.gov/dm/pubs/hemovari-A1C/.

For information on blood stem cell transplantation and HLA matching, visit http://www3.niaid.nih.gov/labs/aboutlabs/lhd/geneticImmunotherapySection/malech.htm

Posted at National Institute of Health

http://www.nih.gov/news/health/dec2009/niddk-09.htm

Cracking the Stem Cell Code Reaches Amazon’s Best Seller List

SAN CLEMENTE, CA, December 29, 2009 /Cambridge Who’s Who/ — Christian Drapeau, Scientist-Author and Co-Founder, Chief Science Officer of STEMTech HealthSciences Inc., has been recognized by Cambridge Who’s Who for his dedication, leadership and excellence in the stem cell science and health fields.

Christian. Drapeau MSc is a pioneer of the stem cell science field and America’s leading advocate for adult stem cell science and medicine. As a leading voice in the field, he travels internationally, lecturing to doctors, scientists, and business leaders on his stem cell research findings and developments in stem cell nutrition, managing operations including research protocols, and the marketing and development of stem cell enhancement products. His bestselling book, Cracking the Stem Cell Code. provides unique and valuable information on adult stem cells and their natural role in the human body. After obtaining his Master of Science in Neurophysiology from McGill University, Christian studied dietary supplements and their effects on the nervous system. While studying the cyanophyta Aphanizomenon flos-aquae, he discovered its enhancing effect on adult stem cells and developed the stem cell enhancer StemEnhance. Christian Drapeau is a member of the International Society for Stem Cell Research.

For more information on Christian and his work in the adult stem cell and stem cell nutrition fields: www.askjacki.stemtechbiz.com or www.christiandrapeau.com

About Cambridge Who’s Who
Cambridge Who’s Who is an exclusive membership organization that recognizes and empowers executives, professionals and entrepreneurs throughout the world. From healthcare to law, engineering to finance, manufacturing to education, every major industry is represented by its 500,000 active members.

Cambridge Who’s Who membership provides individuals with a valuable third party endorsement of their accomplishments and gives them the tools needed to brand themselves and their businesses effectively. In addition to publishing biographies in print and electronic form, Cambridge Who’s Who offers an online networking platform where members can establish new business relationships and achieve career advancement within their company, industry or profession.

For more information, please visit our site: Cambridge Who’s Who.

Stem cell breakthrough may offer possible cures for Diabetes, Parkinson’s disease

Posted in Adult Stem Cell Research,Adult Stem Cells by Jacki Smith on March 14, 2009
Tags: , , , , , , ,

London, March 2 (ANI): Scientists have reached a step closer to developing potential treatments for devastating diseases including spinal cord injury, macular degeneration, diabetes and Parkinson’s disease, thanks to a new method of creating stem cells discovered by researchers at Mount Sinai Hospital in Canada.

The researchers say that their study accelerates stem cell technology, and provides a road map for new clinical approaches to regenerative medicine.

“We hope that these stem cells will form the basis for treatment for many diseases and conditions that are currently considered incurable,” Nature magazine quoted Dr. Andras Nagy, Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Investigator at the McEwen Centre for Regenerative Medicine, and Canada Research Chair in Stem Cells and Regeneration, as saying.

“This new method of generating stem cells does not require embryos as starting points and could be used to generate cells from many adult tissues such as a patient’s own skin cells,” the researcher added.

Dr. Nagy revealed that his method helps create pluripotent stem cells-which can develop into most other cell types-without disrupting healthy genes. The researcher added that the method involves a novel wrapping procedure to deliver specific genes to reprogram cells into stem cells.

Scientists have to date relied upon approaches that requite the use of viruses to deliver the required genes, a method that carries the risk of damaging the DNA.

Given that Dr. Nagy’s method does not require viruses, it overcomes a major hurdle for the future of safe, personalized stem cell therapies in humans.

“This research is a huge step forward on the path to new stem cell-based therapies and indicates that researchers at the Lunenfeld are at the leading edge of regenerative medicine,” said Dr. Jim Woodgett, Director of Research for the Samuel Lunenfeld Research Institute of Mount Sinai Hospital.

Regenerative medicine refers to enabling the human body to repair, replace, restore and regenerate its own damaged or diseased cells, tissues and organs. (ANI)

Will Obama’s Stem Cell Announcement Doom Promising Adult Stem Cell Research? — Stem Cell Business Community Suggests Adult Stem Cell Advances Could Be Lost as Embryonic Researchers Compete for Funding

By: PR Newswire | 12 Mar 2009 | 02:06 PM ET
SAN CLEMENTE, Calif., March 12, 2009 /PRNewswire via COMTEX/ — Adult Stem Cell scientists and businesses are concerned that President Obama’s executive order repealing restrictions on Embryonic Stem Cell research will have the unintended consequence of diverting attention and resources away from the promising Adult Stem Cell scientific advances.

STEMTech HealthSciences is a leading company in the field of Stem Cell Nutrition and its chief executive officer is speaking out to create awareness of Adult Stem Cell science’s need for continued support and resources. Adult Stem Cells are naturally created by a person’s own body while Embryonic Stem Cells are extracted from embryos.

“The amazing advances over the past few years in Adult Stem Cell science, including the Nobel Prize winning advances that led to the discovery that Adult Stem Cells travel to tissues and organs needing renewal and become cells of these organs and tissues, are at risk of being eclipsed because of the media and business furor over Embryonic Stem Cells” said STEMTech CEO Ray Carter.

According to Carter, Embryonic Stem Cell research is a multi-billion dollar industry with Wall Street, the media and now the U.S. government joining in to create visibility and mass funding. Meanwhile, the scientific progress made by companies such as STEMTech which owns the rights to the only patented product proven to enhance Adult Stem Cell release in a person’s own body goes relatively unnoticed.

While not a mediagenic billion dollar player however, STEMTech has grown into 8 countries since 2006 with its Stem Cell Nutrition product line which supports healthy Adult Stem Cell physiology.

Christian Drapeau, author of The Stem Cell Theory of Renewal (March 2009, Sutton Hart http://www.suttonhart.com) and pioneer of the Stem Cell Nutrition field, explains the StemEnhance(R) value proposition that “a natural, mild long term increase in the body’s level of circulating Adult Stem Cells delivers substantial wellness benefits”.

According to Christian Drapeau, who serves as STEMTech’s chief science officer, Adult Stem Cells have the greater potential for human wellness and he echoes Carter’s concern that President Obama’s removing restrictions Embryonic Stem Cell research could divert critical resources away from Adult Stem Cell research.

Media Contact: Maggie Jessup maggie@platformstrategy.com SOURCE STEMTech HealthSciences http://www.prnewswire.com Copyright (C) 2009 PR Newswire. All rights reserved -0-

Patients First Act Adult Stem Cells HR 2807 & HR 877

Richard Burt M.D. has completed a study using adult stem cell therapy on patients that has been published in JAMA – The Journal of the American Medical Association. Three of his patients from the study that had received injections of their own adult stem cells, taken from their bone marrow, spoke in front of lawmakers in Washington DC. They are trying to get funding for the same adult stem cell therapy that has helped them. Dr. David Prentice PhD. of the Family Research Council thanked the bi-partisan group that sponsored the bill H.R. 2807 The Patient First Act that would seek funding for the therapies that wil help the patients first. The public should call lawmakers and have support them support the bill.

How can we approve Embryonic Stem Cell legislation? Especially when there is no proof of any true merit and comes with life threatening side effects… then hold out on funding for adult stem cell therapy which has scientific studies proving its effectiveness. The legislation that was introduced above H.R. 2807 was introduced but never made it out of committee.  See below.

H.R. 2807:  Patients First Act of 2007
  Introduced Jun 21, 2007
  Reported by Committee (did not occur)
  Voted on in House (did not occur)
  Voted on in Senate (did not occur)
  Signed by President (did not occur)
This bill never became law. This bill was proposed in a previous session of Congress. Sessions of Congress last two years, and at the end of each session all proposed bills and resolutions that haven’t passed are cleared from the books. Members often reintroduce bills that did not come up for debate under a new number in the next session.

So it was reintroduced on Feb. 4, 2009 as H.R. 877:  Patients First Act of 2009. It was submitted to the House Committee on Energy and Commerce which has 59 members. Here is a link to all the members and all the bills that they are overseeing http://twurl.nl/0mrnuo .

Please join with me and write your representatives and tell them we want H.R. 877  passed. We should have the opportunity to intensify stem cell research which has already been showing evidence of substantial clinical benefit to patients, and for other purposes, and in an ethical manner.  The latest info on the bill is below and I will continue to update it.

H.R. 877:  Patients First Act of 2009

  Introduced Feb 4, 2009
  Referred to Committee View Committee Assignments
  Reported by Committee (pending)
  Voted on in House (pending)
  Voted on in Senate (pending)
  Signed by President (pending)

This bill is in the first step in the legislative process. Introduced bills and resolutions first go to committees that deliberate, investigate, and revise them before they go to general debate. The majority of bills and resolutions never make it out of committee. [Last Updated: Mar 7, 2009 11:31AM]

For more information on stem cell enhancers which aid our bodies in releasing our own adult bone marrow stem cells feel free to visit my website www.stemcellhotline.com. Leave me a comment to let me know what you think of the politics involved with this subject.

Story of Christian Drapeau MSc. and StemEnhance

christian-drapeau2This is the story of how Christian Drapeau MSc. Chief Science Officer & Co-Founder of StemTech Health Sciences helped develop StemEnhance
A little over two decades ago, a new herbal supplement named Aphanizomenon flos-aquae (AFA), an aquatic botanical, made its appearance on the marketplace. Rapidly, AFA became popular for the wide variety of health benefits reported by consumers. Over the years we identified the presence in AFA of various bioactive compounds such as phycocyanin, a strong natural anti-inflammatory compound, a polysaccharide supporting immune function, and phenylethylamine (PEA), a molecule knows as “the molecule of love,” which increases mental clarity and provides a sense of well-being. Nevertheless, in spite of the identification of these various components, many health benefits reported by consumers remained unexplained.
At the turn of the 21st century, data began appearing in the scientific literature describing the potential of embryonic stem cells (ESC). Embryonic stem cells were shown to have the ability to become any kind of cells in the body. Soon after, studies revealed that adult stem cells (ASC) also had the ability of becoming virtually any kind of cells in the body. When this discovery was made, we hypothesized that adult stem cells constituted the natural renewal system of the body, and we published this hypothesis in the journal, Medical Hypotheses (October 2002). Our idea at the time was this: if adult stem cells indeed constituted the natural renewal system of the body, with adult stem cells being able to become any cell type of the body, then supporting this process could lead to a wide variety of health benefits. Given the broad spectrum of benefits reported by AFA consumers, we simply hypothesized that AFA was supporting aspects of stem cell physiology.
With this in mind, we initiated a series of laboratory experiments and soon discovered that consumption of large quantity of AFA (greater than 5 grams) increased the number of circulating stem cells by up to 30%. As we pursued our investigation to identify the compound in AFA responsible for this effect, we actually identified two specific compounds supporting both the release of stem cells from the bone marrow and their migration out of the blood into tissues. We then proceeded to concentrate these compounds out of AFA, achieving 5:1 concentrates for both compounds, and blended these compounds to make StemEnhance. One gram of StemEnhance supports the release of stem cells from the bone marrow and increases the number of stem cells from the bone marrow and increases the number of circulating stem cells by up to 30%. StemEnhance also concentrates phycocyanin and PEA, other important compounds found in AFA.
StemEnhance is a natural product made of 100% organic AFA and manufactured in accordance with GMP regulations. The powder is encapsulated and bottled in a pharmaceutical grade facility, providing the highest quality possible. Each lot of StemEnhance is tested for any potential contaminants, according to a stringent quality control program.
When asked why would one want to take StemEnhance, the answer is simply to support the body’s natural process of maintaining optimal health. Supporting stem cell physiology everyday by increasing the number of circulating stem cells is one of the wisest decisions one can make to regain and maintain optimal health.
Jacki Smith  – Health Coach 817.510.3600
askjacki@gmail.com   www.stemcellhotline.com